o_19ntugujs11ikbdrctt1teabbla.pdf

· The prognosis for platinum-resistant ovarian cancer is currently poor, and leaves a wide gap
where companies can fill with innovative solutions.
Thus, the demand for maintenance therapies is high in the Asia Pacific ovarian cancer market.
Moreover, the time is right for
market players to invest in developing more effective treatment solutions for patients that are
afflicted with platinum-sensitive ovarian cancer.
· Approvals for olaparib and trebananib, two promising drug candidates for the treatment of
ovarian cancer, are expected to come through before 2020.
But even after being approved, their penetration rates will remain somewhat restricted to the
surface of the ovarian cancer market. Currently, the ovarian cancer therapeutics pipeline is
rather crowded, but it still leaves a lot to be desired on the efficacy of late-stage drugs. Only
minimal improvements have been observed in progression-free survival rates.
Browse the full Press Release of Ovarian Cancer Market : http://www.mrrse.com/ovariancancer-therapeutics-market-report
Based on the factors discussed above, it can be said that the ovarian cancer market in Asia
Pacific will not be driven by new drug approvals.
Growth will primarily be a result of inflation and the general rise in the prevalence rates of
ovarian cancer. On the positive side, the large number of drug candidates in the ovarian
cancer pipeline will keep the industry’s interest levels and degree of competition moderately
high.
Send An Enquiry: http://www.mrrse.com/enquiry/112
Table of Contents:
1.1 List of Tables
1.2 List of Figures